Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call scheduled for February 25, 2021, at 4:30 p.m. Eastern Time. The call will cover the Company’s financial results and provide a corporate update.
To participate, call (877) 407-8037 (U.S.) or (201) 689-8037 (International), referencing the “Collegium Pharmaceutical Q4 2020 Earnings Call.” A replay will be available on the Company’s website shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) announced its financial guidance for 2021, projecting Xtampza ER revenues between $155 million and $165 million and Nucynta franchise revenues between $175 million and $185 million. Adjusted EBITDA is expected between $160 million and $170 million, with total operating expenses projected between $125 million and $135 million. The company aims to leverage its cost structure and generate significant cash flow from operations while focusing on maximizing the potential of its pain management portfolio.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong Q3 2020 results, achieving record net income of $11.3 million and generating $34.2 million in cash flow from operations. Xtampza ER revenues rose 21% year-over-year to $32.1 million, while Nucynta revenues were $47.1 million. Operating expenses decreased by 12%, enhancing profitability, as reflected in an adjusted EBITDA of $41.8 million. Collegium secured exclusive formulary access for Xtampza ER with a national Medicare Part D plan, covering over 92 million lives, and settled patent litigation with Teva, allowing its generic launch in 2033.
Collegium Pharmaceutical announced the publication of a postmarketing analysis titled “Misuse, Abuse and Diversion of Xtampza ER,” featured in Pain Medicine. This study highlights that, despite a 50-fold increase in prescriptions for Xtampza ER following its launch, incidents of misuse, abuse, and diversion remained low. The analysis utilized RADARS® data to compare Xtampza ER to other opioid formulations. The company emphasized its commitment to ongoing studies and surveillance to contribute to the understanding of abuse-deterrent formulations.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will host a conference call on November 5, 2020, at 4:30 p.m. ET. This call will focus on the Company's Q3 financial results and corporate updates. Investors can participate by dialing (877) 407-8037 or (201) 689-8037 for international access, and the audio webcast will be available on the Company's website. Recordings of the event will be retrievable shortly after its conclusion. Collegium aims to lead in responsible pain management with its headquarters in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) reached a settlement with Teva Pharmaceutical regarding patent litigation over the generic version of Xtampza ER. The agreement allows Teva to market its generic version starting September 2, 2033, pending FDA approval. The settlement confirms that Teva's proposed products infringe on Collegium's patents, which are valid and enforceable. Collegium's intellectual property portfolio includes 19 patents for Xtampza ER, valid through 2036, asserting the company's commitment to innovation in pain management.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has appointed Dr. Rita Balice-Gordon to its Board of Directors, effective September 24, 2020. Dr. Balice-Gordon brings extensive scientific expertise, having served in senior roles at Muna Therapeutics and Sanofi, and as former Vice President at Pfizer. Collegium aims to enhance its leadership in responsible pain management through her insights. Management is optimistic about the contributions she will make during this significant phase in the company’s evolution.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced five poster presentations at the 14th Annual PAINWeek National Conference held virtually from September 11-13, 2020.
The posters focused on data related to abuse and misuse of its products, including Xtampza® ER and Nucynta® ER. The findings were aimed at reinforcing the company’s commitment to responsible pain management and addressing concerns about opioid abuse. Richard Malamut, M.D., emphasized the importance of sharing real-world evidence at this scientific forum.
Collegium Pharmaceutical (Nasdaq: COLL) announced five poster presentations at the virtual 14th Annual PAINWeek National Conference from September 11-13, 2020. These presentations focus on the company's pain management products, particularly Xtampza® ER, and explore topics such as its nonmedical use, online perceptions, diversion rates, and abuse potential compared to other opioids. The conference aims to highlight critical data regarding responsible pain management practices and the risks associated with opioid use. Important safety information regarding addiction and respiratory depression is also provided.
Collegium Pharmaceutical (Nasdaq: COLL) reported strong financial results for Q2 2020, achieving a non-GAAP net income of $33.2 million and generating $43.9 million in cash from operations. Xtampza ER's net revenue rose 29% year-over-year to $33.6 million, with total prescriptions increasing by 22%. The company also added two new formulation patents for Xtampza ER, extending patent coverage to 2030 and 2036. Nucynta ER's market share reached 6.2%. Despite increased operating expenses of $31.8 million, Collegium is poised for a financially transformative year.